8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 30, 2026·SEC
Material company update
Feb 17, 2026·SEC
Annexon, Inc.(ANNX)Earnings, Financials & Key Ratios
ANNX•NASDAQ
$5.48
Price updated Jun 27, 2026
AboutAnnexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.Show more
- Revenue$0
- EBITDA-$214M-41.9%
- Net Income-$207M-49.6%
- EPS (Diluted)-1.34-32.7%
- ROE-81.9%-61.1%
ANNX Price & Volume
Annexon, Inc. (ANNX) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Challenges Long-Term Solvency
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding dependency
"Annexon remains a pre-revenue biotechnology entity heavily dependent on external capital to fund its intensive R&D pipeline, which reached a quarterly peak of $49.7 million in 2025Q3. While the company maintains a low debt-to-equity ratio of 0.12, the accumulation of a $961.5 million deficit suggests that future equity dilution is highly probable to sustain operations. Investors should monitor the company's ability to reach commercialization milestones before its $175.2 million cash position is further eroded by ongoing operating losses."
Verdict Logic
the company's lack of revenue and consistent quarterly cash burn, which reached $46.8 million in 2026Q1, creates a high risk of future shareholder dilution to fund essential clinical development.
ANNX Growth Metrics
Annexon, Inc. (ANNX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-17.38%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-3.39%
Return on Capital
10 Years-97.76%
5 Years-56.08%
3 Years-60.82%
Last Year-78.05%
ANNX Recent Earnings
Annexon, Inc. (ANNX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.23+23.3%
$0.30
Rev
—
$6M
Q2 2026
Mar 30, 2026Metric
Actual
Est
EPS
$0.28+12.5%
$0.32
Rev
—
$3M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.37-8.8%
$0.34
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.34+5.6%
$0.36
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.23vs $0.30+23.3% | —vs $6M |
| Q2 2026 | Mar 30, 2026 | $0.28vs $0.32+12.5% | —vs $3M |
| Q4 2025 | Nov 10, 2025 | $0.37vs $0.34-8.8% | — |
| Q3 2025 | Aug 14, 2025 | $0.34vs $0.36+5.6% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Annexon, Inc. (ANNX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.48 | $1.06B | -4.09 | — | — | -81.9% | 0.22% | |
| $34.81 | $3.58B | -42.98 | 120.01% | -49.17% | -5.89% | — | |
| $327.79 | $9.47B | -24.32 | -100% | — | -43.02% | — | |
| $27.00 | $3.38B | -207.69 | 91.34% | -0.57% | -1.41% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $41.03 | $5.25B | 227.94 | 28.46% | 12.95% | 39.71% | — |
Compare ANNX vs Peers
Annexon, Inc. (ANNX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ANNX SEC Filings & Documents
Annexon, Inc. (ANNX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ANNX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ANNX Frequently Asked Questions
Annexon, Inc. (ANNX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is ANNX profitable?
Annexon, Inc. (ANNX) reported a net loss of $196.5M for fiscal year 2025.
Dividend & Returns
Does ANNX pay dividends?
Yes, Annexon, Inc. (ANNX) pays a dividend with a yield of 0.22%. This makes it attractive for income-focused investors.
What is ANNX's return on equity?
Annexon, Inc. (ANNX) has a return on equity (ROE) of -81.9%. Negative ROE indicates the company is unprofitable.
What is Annexon, Inc.'s free cash flow?
Annexon, Inc. (ANNX) had negative free cash flow of $183.2M in fiscal year 2025, likely due to heavy capital investments.